In patients with Stage 3 and 4 CKD, the drug reduced [PTH] by 43.1%, but simultaneously kept mean [Ca]s between 8.5 and 9.0 mg/dL even though ECa rose or remained unchanged [71]. The gene discussed is PTH; the disease is chronic kidney disease.